Adagene, Inc. (ADAG)
| Market Cap | 630.12M |
| Revenue (ttm) | 1.75M |
| Net Income (ttm) | n/a |
| Shares Out | 43.58M |
| EPS (ttm) | -2.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,784 |
| Open | 14.63 |
| Previous Close | 15.22 |
| Day's Range | 14.24 - 14.70 |
| 52-Week Range | 11.11 - 31.83 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 33.89 (+130.5%) |
| Est. Earnings Date | n/a |
About ADAG
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of variou...
Financial Performance
In 2020, Adagene's revenue was $700,913, an increase of 46.02% compared to the previous year's $480,000. Losses were -$42.40 million, 158.0% more than in 2019.
Financial StatementsNews
Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming...
Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates
- Established three clinical collaborations with Merck to conduct global combination trials with pembrolizumab for three clinical-stage oncology candidates -
Adagene Inks Third Cancer Trial Collaboration With Merck
Adagene Inc (NASDAQ: ADAG) has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The agreement includes an open-label, dose-escalation, and expansio...
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combina...
Collaboration to evaluate NEObody™ product candidate, ADG106, in combination with KEYTRUDA® for patients with advanced or metastatic solid and/or hematological malignancies Collaboration to evaluate NEO...
Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory B...
- Global immuno-oncology experts bring decades of experience to advance company's transformative research and development pipeline - - Global immuno-oncology experts bring decades of experience to advan...
Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors
Adagene Inc (NASDAQ: ADAG) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The agreement includes two clinical studies to evaluate Adagene's anti-C...
Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (AD...
Two global clinical studies to evaluate NEObody™ product candidate, ADG116, and SAFEbody™ product candidate, ADG126, in combination with KEYTRUDA® (pembrolizumab) for patients with advanced/metastatic s...
Adagene Announces Authorization of Share Repurchase Program up to US$20 Million
SAN FRANCISCO and SUZHOU, China, July 07, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the disc...
Adagene Announces Inclusion in FTSE Russell Indexes
SAN FRANCISCO and SUZHOU, China, June 16, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the dis...
Adagene to Present at Upcoming Investor Conferences
SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming t...
Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual ...
-Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement
Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Researc...
SAN FRANCISCO and SUZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the dis...
Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates
- Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds- -Reported clinical data for anti-CD137 and two anti-CTLA-4 programs- -Advanced five discovery pro...
Adagene Announces Clinical Advancement for ADG116
-NEObody™ product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial- -Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism- -Poised for global ex...
Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program
SAFEbody technology enables precision masking of antibodies for enhanced safety SAFEbody technology enables precision masking of antibodies for enhanced safety
Adagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the disco...
Adagene Inc. Announces Pricing of Initial Public Offering
SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming t...
Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate T...
Exelixis, Inc. (Nasdaq: EXEL) and Adagene today announced a collaboration and license agreement under which Exelixis will utilize Adagene’s SAFEbody™ technology platform...
Chinese cancer biotech Adagene files for a $125 million US IPO
Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, filed on Tuesday with the SEC to raise up to $125 million in an initial public offering.
Adagene IPO Registration Document (S-1)
Adagene, Inc. has filed to go public with an IPO on the NASDAQ.
News briefing: AbbVie selects first target for Dragonfly partnership; Cognito nets BDD for Alzheimer's treatment device
Dragonfly’s partnership with AbbVie is beginning to bear fruit. AbbVie has selected its first NK cell engager-based immunotherapy as part of the deal, triggering an undisclosed opt-in payment, the compa...
Adagene Achieves CAR-T Collaboration Milestone
Yields potential first-ever antibodies targeting human endogenous retrovirus associated with kidney cancer.